<DOC>
	<DOCNO>NCT00697853</DOCNO>
	<brief_summary>This study undertaken ass immune response safety profile 4 lot novel adjuvanted hepatitis B vaccine formulate follow different process , Engerix™-B control vaccine</brief_summary>
	<brief_title>Immunogenicity Safety GSK Biologicals ' HBV-MPL Vaccine ( 2 Doses ) , Engerix™-B ( 3 Doses ) Healthy Adults</brief_title>
	<detailed_description>This open , randomize study five group , four group receive HBV-MPL candidate vaccine double-blinded . At time conduct study , sponsor GlaxoSmithKline know former name SmithKline Beecham</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male female 15 50 year age time first vaccination . Free obvious health problem establish medical history clinical examination enter study . Written inform consent obtain subject and/or parent guardian subject . If subject female , must nonchildbearing potential , , childbearing potential , must abstinent use adequate contraceptive precaution one month prior vaccination two month last vaccination Use investigational nonregistered drug vaccine study vaccine ( ) study period within 30 day precede first dose study vaccine . Administration chronic ( defined 14 day ) immunosuppressant immunemodifying drug within six month vaccination . Planned administration/ administration vaccine foreseen study protocol period start 30 day dose vaccine end 30 day . Previous vaccination hepatitis B . History significant persist hematological , hepatic , renal , cardiac respiratory disease . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . A family history congenital hereditary immunodeficiency . History allergic disease reaction likely exacerbate component vaccine . Acute disease time enrollment . Hepatomegaly , right upper quadrant abdominal pain tenderness . Oral temperature ≥37.5°C ( 99.5°F ) . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration/ administration study period . Pregnant lactate female . History chronic alcohol consumption and/or intravenous drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>Adjuvanted hepatitis B vaccine</keyword>
	<keyword>Recombinant hepatitis B vaccine</keyword>
</DOC>